MS relapses

Mavenclad found comparable to Gilenya in highly active MS

Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups ā€” but…

Switching to Ocrevus Over Other MS Therapies Means Fewer Relapses

People with relapsing-remitting multiple sclerosis (RRMS) whoĀ switch to Ocrevus (ocrelizumab) after discontinuing Gilenya (fingolimod) have fewer relapses than those who switch to Mavenclad (cladribine) orĀ Tysabri (natalizumab), according to a new study. Rates of disability worsening were similar for Ocrevus and Tysabri, but patients who switched…

Study Ties Antinuclear AntibodiesĀ to Inflammation, Relapses

The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with multiple sclerosis (MS). That finding from a small study indicates high levels of these antinuclear antibodies were correlated with relapse status and ongoing inflammation in MS. The study, ā€œAntinuclear…

Recognizing Pseudo Exacerbations in MS

My readers have recently brought something to my attention: They informed me that not all MS exacerbations (flare-ups, relapses, and attacks) are created equal. I have learned that along with the hardcore types, which usually require steroid treatment, there are also pseudo-exacerbations. I can always trace the causes of…